NCT07768579Recruiting
The Effect of Sequential Therapy on Alzheimer's Disease
The Effect of Sequential Therapy on Alzheimer's Disease: A Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to learn how Alzheimer's disease changes over time in people at different stages of the disease. It will look at changes in memory and thinking, daily activities, behavior, and traditional Chinese medicine symptom patterns. It will also learn about the outcomes and safety of sequential traditional Chinese medicine treatment based on the stage of Alzheimer's disease. The main questions this study aims to answer are: * How do memory and thinking, daily activities, behavior, and traditional Chinese medicine symptom patterns naturally change over time in participants with early-, middle-, and late-stage Alzheimer's disease? * How do symptoms and traditional Chinese medicine symptom patterns change together as Alzheimer's disease progresses? * Do participants receiving stage-based sequential traditional Chinese medicine treatment have different changes in memory and thinking, daily activities, behavior, and overall disease status? * What medical problems or side effects occur during sequential traditional Chinese medicine treatment? About 600 participants aged 55 to 85 years will take part in this study. Participants will be followed for 12 months. Participants will: * Visit the study center at the start of the study and at 3, 6, 9, and 12 months. * Complete assessments of memory and thinking, daily activities, behavior, overall disease status, and traditional Chinese medicine symptoms. * Have blood tests and other study examinations. * Have their treatment use and medical problems recorded during follow-up.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- 30 Apr 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Dongzhimen Hospital, Beijing
- Diseases
- Alzheimer disease
- NCT number
- NCT07768579
What you commit to
- Study type: Observational
- Planned participants: 600
- From 30 Apr 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications affecting cognitive function within 4 weeks before enrollment.
Other illness
- Cerebrovascular disease, traumatic brain injury, thyroid dysfunction, vitamin deficiency, or other diseases sufficient to cause cognitive impairment.
- Malignant tumors unrelated to the target disease, hematological diseases, severe psychiatric disorders, depression, or anxiety disorders.
- Severe dysfunction of major organs, including the heart, brain, liver, or kidneys.
- Infectious diseases, including HIV or HBV infection.
- Gastrointestinal diseases that may affect drug absorption.
Other
- Pregnancy, breastfeeding, or plans for pregnancy in the near future.
- Recent participation in or current participation in another trial.
Who the study is looking for
- Age 55 to 85 years, regardless of sex.
- Memory decline reported by the participant or family member for at least 6 months.
- Meets the diagnostic criteria for the target disease and is clinically diagnosed with mild cognitive impairment due to Alzheimer's disease or mild, moderate, or severe Alzheimer's dementia.
- Able to complete clinical scale assessments and blood sampling.
- Able to undergo brain magnetic resonance imaging (MRI) or amyloid-beta positron emission tomography (Aβ-PET) examinations using the tracers specified in the study protocol.
- Written informed consent provided by the participant or a legally authorized representative.
- Able to complete study follow-up.
- Participants with a known allergy to components of the exposure medications will be assigned to the non-exposed group.
Age in the registry: 55 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dongzhimen Hospital, Beijing University of Chinese Medicine Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.